泰格医药 (300347)

Hangzhou Tigermed Consulting Co.,Ltd.

ASZ

Tags

300ESG Index300 Non-Cyclical IndexAIGC ConceptAI HealthcareContract Research Organization (CXO)MSCI Component StocksCSI 200 IndexInnovative DrugsSTAR and ChiNext 50 IndexContains H-SharesFund Reduction PositionsFund Heavy PositionsCSI 300 IndexResearch and Experimental DevelopmentSocial Security Fund Heavy PositionsHigh-Performing StocksMargin Trading and Securities LendingNon-Cyclical StocksSME & ChiNext 100 IndexChiNext 300 IndexChiNext Large CapChiNext 50 IndexChiNext IndexChiNext HealthcareSZSE 300 Index

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 86102.61
  • Circulating A-Shares(W): 56621.42
  • Earnings Per Share(RMB): 1.1900
  • Net Assets Per Share(RMB): 24.5943
  • Operating Revenue(W RMB): 502586.83
  • Total Profit(W RMB): 122278.08
  • Net Profit Attributable to Parent(W RMB): 102043.42
  • Net Profit Growth Rate(%): 25.45
  • Weighted Return on Equity(%): 4.8900
  • Operating Cash Flow Per Share(RMB): 0.8590
  • Undistributed Profit Per Share(RMB): 10.9782
  • Capital Reserve Per Share(RMB): 12.3323

2. Main Business

The main business covers:

  • Providing full-process professional services for clinical trials in new drug research and development

3. Company Basic Information

  • Company Name: Hangzhou Tigermed Consulting Co., Ltd.
  • Listing Date: 2012-08-17
  • Industry: Research and Experimental Development
  • Address: 20th Floor, Building 8, No. 19 Jugong Road, Xixing Street, Binjiang District, Hangzhou City, Zhejiang Province, China
  • Website: www.tigermedgrp.com
  • Company Profile: The Company was established through the overall change of Tigermed Co., Ltd. into a joint stock company. On August 4, 2010, the board of directors of Tigermed Co., Ltd. resolved that all shareholders of Tigermed Co., Ltd. would act as promoters, converting the company into a joint stock company based on the audited net assets of Tigermed Co., Ltd. as of May 31, 2010, which amounted to RMB 67,647,753.65, at a ratio of 1:0.5913, resulting in 40,000,000 shares, with the remaining RMB 27,647,753.65 credited to capital reserve. Lixin Certified Public Accountants verified the above capital contribution and issued the “Capital Verification Report” (Xin Hui Shi Bao Zi (2010) No. 11964) on September 15, 2010. On September 8, 2010, the Hangzhou Foreign Trade and Economic Cooperation Bureau issued the “Administrative License Decision on Approving the Change of Hangzhou Tigermed Consulting Co., Ltd.” (Hang Wai Jing Mao Wai Fu Xu [2010] No. 276), approving the overall change of Tigermed Co., Ltd. into a joint stock company. On November 4, 2010, the company completed the industrial and commercial registration change and obtained the business license with registration number 330100400022052. On March 15, 2011, the Hangzhou Foreign Trade and Economic Cooperation Bureau issued the “Filing Form for Non-Substantive Changes to Contracts and Articles of Association of Foreign-Invested Enterprises” (No.: XK-3-2011011), approving the change of the name of the corporate shareholder of Tigermed. On March 17, 2011, Tigermed exchanged for the “Approval Certificate for Enterprises with Investment from Taiwan, Hong Kong, Macao and Overseas Chinese” (Approval No.: Shang Wai Zi Zhe Fu Zi Hang Zi [2008] No. 07448, Serial No.: 3300069691).

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Hong Kong Securities Clearing Company Ltd. Northbound Capital 4836.25 8.54
2 China Europe Healthcare Hybrid Securities Investment Fund Class A Fund 2885.17 5.10
2 China Europe Healthcare Hybrid Securities Investment Fund Class A Fund 2885.17 5.10
3 HuaBao CSI Healthcare ETF Fund 1456.80 2.57
4 National Social Security Fund Portfolio 601 Social Security Fund 1145.36 2.02
5 E Fund ChiNext ETF Fund 1125.86 1.99
6 Huatai-PineBridge CSI 300 ETF Fund 877.79 1.55
7 China Merchants SSE Bio-medicine Index Fund (LOF) Class A Fund 752.96 1.33
8 Noah Pioneer Hybrid Securities Investment Fund Class A Fund 311.31 0.55
9 Tianhong SSE Bio-medicine ETF Fund 264.22 0.47
10 Tianhong Pharmaceutical Innovation Hybrid Securities Investment Fund Class A Fund 140.78 0.25

5. Concept Sectors

  • H-Share
  • CXO Concept
  • AIGC Concept
  • Innovative Drug
  • AI Healthcare
  • Margin Trading & Securities Lending
  • High-Performance Stock
  • Social Security Fund Heavy Holdings
  • Fund Heavy Holdings
  • MSCI Constituent
  • Fund Reduction
  • Non-Cyclical Stock
  • Zhongchuang 100
  • ChiNext Index
  • SZSE 300
  • CSI 300
  • ChiNext 50
  • Chuangye 300
  • CSI 200
  • 300 Non-Cyclical
  • ChiNext Large Cap
  • Chuang Quality
  • Chuang Healthcare
  • STAR 50
  • 300 ESG

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information